Compare
Rapport Therapeutics, Inc. vs Rigel Pharmaceuticals Inc vs Ardelyx, Inc. vs Syndax Pharmaceuticals Inc
| Latest fiscal year | Rapport Therapeutics, Inc. RAPP | Rigel Pharmaceuticals Inc RIGLRevenue covers only part of its income (partial revenue) | Ardelyx, Inc. ARDX | Syndax Pharmaceuticals Inc SNDX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | $407.32M | $172.35M |
| Revenue growth (YoY) | n/a | n/a | +22.1% | +627.8% |
| Gross margin | n/a | n/a | 90.3% (computed) | n/a |
| Operating margin | n/a | n/a | -10.1% | -158.4% |
| Net margin | n/a | n/a | -15.1% | -165.6% |
| Net income | -$111.48M | $367.02M | -$61.60M | -$285.42M |
| EPS (Diluted) | -$2.86 | $19.48 | -$0.26 | -$3.29 |
| Operating cash flow | -$87.47M | $75.66M | -$42.48M | -$322.98M |
| Free cash flow | -$88.09M | n/a | -$43.98M | -$323.17M |
| Cash & equivalents | $52.65M | $40.58M | $68.00M | $134.93M |
| Total assets | $512.43M | $513.59M | $501.60M | $529.71M |
| Total liabilities | $27.78M | $122.11M | $334.65M | $465.08M |
| Shareholders' equity | $484.65M | $391.48M | $166.95M | $64.63M |
| Return on year-end equity | -23.0% | 93.8% | -36.9% | -441.6% |
| Shares outstanding | 47.77M | 18.31M | 244.35M | 87.41M |
Revenue, most recent five fiscal years
| Fiscal year | Rapport Therapeutics, Inc. | Rigel Pharmaceuticals Inc | Ardelyx, Inc. | Syndax Pharmaceuticals Inc |
|---|---|---|---|---|
| Latest | n/a | n/a | $407.32M Ended 2025-12-31 | $172.35M Ended 2025-12-31 |
| 1 year earlier | n/a | n/a | $333.62M Ended 2024-12-31 | $23.68M Ended 2024-12-31 |
| 2 years earlier | n/a | n/a | $124.46M Ended 2023-12-31 | $0 Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | $52.16M Ended 2022-12-31 | $0 Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | $10.10M Ended 2021-12-31 | $139.71M Ended 2021-12-31 |